{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:55:07Z","timestamp":1791924907589,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T00:00:00Z","timestamp":1540080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004686","name":"Deanship of Scientific Research, King Faisal University","doi-asserted-by":"publisher","award":["180009"],"award-info":[{"award-number":["180009"]}],"id":[{"id":"10.13039\/501100004686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Preclinical Research &amp; Development<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n<\/jats:table-wrap><\/jats:p><jats:p>Appropriate translation and determination of the maximum recommended starting dose in human is a vital task in new drug development and research. Allometric scaling is the most frequently used approach for dose extrapolation based on normalization of dose\u2010to\u2010body surface area. Misinterpretation of allometric dose conversion and safety factor application can lead to major problems in calculating maximum recommended safe starting dose in first\u2010in\u2010human clinical trials. Therefore, dose translation always necessitates careful consideration of body surface area, pharmacological, physiological and anatomical factors, pharmacokinetic parameters, metabolic function, receptor, and life span. The concept of estimating the first\u2010in\u2010human dose, interspecies scaling between species and the factors influencing the dose escalation were reviewed. The pros and cons of various approaches to determine first\u2010in\u2010human dose including allometric scaling, pharmacokinetically guided approach, minimal anticipated biological effect level, pharmacokinetic\u2013pharmacodynamic modeling, similar drug approach, and microdosing were explained. The five steps to estimate maximum recommended starting dose for human studies by scaling factor were elaborated. Few examples, illustrating the application of different approaches were also demonstrated along with concerns that may be considered while applying such methods. Furthermore, typical considerations in dose administration, dosing through diet, maximum absorbable dose, blood sampling, and anesthesia in animal species were discussed. In summary, this review may serve as a concise guide for predicting human equivalent dose from animal species for researchers involved in various phases of preclinical and early clinical drug development.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ddr.21461","type":"journal-article","created":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T04:20:24Z","timestamp":1540095624000},"page":"373-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":466,"title":["Dose translation between laboratory animals and human in preclinical and clinical phases of drug development"],"prefix":"10.1002","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-8669","authenticated-orcid":false,"given":"Anroop","family":"Nair","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Clinical Pharmacy, King Faisal University  Al\u2010Ahsa Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Aly","family":"Morsy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Clinical Pharmacy, King Faisal University  Al\u2010Ahsa Saudi Arabia"},{"name":"Department of Pharmacology, Faculty of Medicine Minia University  El\u2010Minia Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1851-6673","authenticated-orcid":false,"given":"Shery","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy, Gulf Medical University  Ajman UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,21]]},"reference":[{"key":"e_1_2_13_2_1","volume":"24","author":"American Society of Laboratory Animal Practitioners","year":"1991","journal-title":"SYNAPSE"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009974107"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155001"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1367-5931(00)00228-3"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2004.08.004"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.727"},{"key":"e_1_2_13_8_1","unstructured":"EMA. (2007). Guideline on strategies to identify and mitigate risks for first\u2010in\u2010human clinical trials with investigational medicinal products. Retrieved fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2017\/07\/WC500232186.pdf"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1201\/b18705-17"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1399-2_1"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9216-1_5"},{"key":"e_1_2_13_12_1","first-page":"66","article-title":"Approximate relation of parts per million in the diet to mg\/kg D.W.\/day. Association of Food and Drug Officials","volume":"18","author":"Lehman A. J.","year":"1954","journal-title":"Quarterly Bulletin"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250701648008"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00513.x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.05.015"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003254631"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603925"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-0105.177703"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.72350"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.04.003"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-001-0405-6"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00267.x"},{"issue":"3","key":"e_1_2_13_23_1","first-page":"1","article-title":"Interpretation of animal dose and human equivalent dose for drug development","volume":"31","author":"Shin J. W.","year":"2010","journal-title":"The Journal of Korean Oriental Medicine"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.5599\/admet.1.4.10"},{"issue":"5","key":"e_1_2_13_25_1","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner P. V.","year":"2011","journal-title":"Journal of the American Association for Laboratory Animal Science"},{"key":"e_1_2_13_26_1","volume-title":"Guidance for industry: Estimating the maximum safe starting dose in adult healthy volunteer","author":"US FDA","year":"2005"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470571224.pse199"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.03.014"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2040-4603.2014.tb00540.x"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9332-y"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ddr.21461","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:37:22Z","timestamp":1760416642000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,21]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/ddr.21461"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21461","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,21]]},"assertion":[{"value":"2018-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}